Metsä Tissue Brand Lambi Begins Using Renewable Fuels for Transport in Sweden

Lambi, a Metsä Tissue brand, has started using a renewable fuel driven truck in one of its transport routes in Sweden from the beginning of the year. This enables a reduction of 90 percent in greenhouse gas emissions per each truckload transported with renewable fuels.

For Metsä Tissue and its consumer brand Lambi, continuous improvement throughout the value chain is essential to sustainability. The objective is to contribute to people’s well-being and to strive to minimize the environmental impacts of the operations and products throughout their life cycle -- from sourcing of raw materials to production and delivery to customers. Metsä Tissue utilizes fresh wood fibers as the main raw material in Lambi tissues to enable efficient tissue paper production. Additionally, transportation plays an important role in the sustainable value chain and therefore the reduction of CO2 emissions during transportation is of high priority in Metsä Tissue.

The Lambi branded biofuel truck runs on renewable diesel (HVO) which has a reduction in greenhouse gas emissions of as much as 90 percent in comparison to fossil-based diesel. The new biofuel driven Lambi truck enables achieving an annual reduction of 120 tons of CO2 emissions. This equals to a passenger car driving 700,000 km, or almost 18 laps around the globe.

"For Lambi, caring for the environment means, among many other things, delivering products in an environmentally conscious way. This route is our first step in Sweden and we are taking actions to increase the amount of routes when suitable transport capacity becomes available” says Katariina Kukkonen, marketing director, Nordics.

"It is important to offer sustainable choices of tissue products and make the actions on sustainable development visible. This way we can help consumers to contribute to a more sustainable future by filling their shopping carts with sustainably produced, local products. Lambi products are a good example of this," continues Kukkonen.

Back to Tissue360 Newsletter